AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
IO Biotech to Announce Pivotal Phase 3 Trial Results on August 11, 2025.
ByAinvest
Sunday, Aug 10, 2025 8:11 am ET1min read
IO Biotech will hold a conference call and webcast on August 11, 2025, to disclose the topline results of its Phase 3 trial of Cylembio, a cancer vaccine, in combination with pembrolizumab for unresectable or metastatic melanoma. The company's management team will discuss the results, which will be available on the IO Biotech website following the event.
IO Biotech (NASDAQ: IOBT), a clinical-stage biopharmaceutical company, has scheduled a conference call and webcast for August 11, 2025, at 8:30 AM ET to reveal the topline results from its pivotal Phase 3 trial (IOB-013/KN-D18) of Cylembio, an investigational immune-modulatory cancer vaccine, in combination with KEYTRUDA® (pembrolizumab) versus KEYTRUDA® alone for first-line treatment of advanced melanoma.The trial, which focuses on patients with unresectable or metastatic melanoma, will be discussed by the company's management team. The live event will be accessible via a webcast or teleconference. A replay will be available on the IO Biotech website following the event.
IO Biotech is developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. Cylembio, the lead candidate, has shown promising results in Phase 1/2 trials in combination with KEYTRUDA®, leading to a Breakthrough Therapy Designation from the US Food and Drug Administration for the treatment of advanced melanoma.
For further information, interested parties can visit the IO Biotech website at www.iobiotech.com or contact Maryann Cimino, Director of Investor Relations, at 617-710-7305 or mci@iobiotech.com.
References:
[1] https://www.stocktitan.net/news/IOBT/io-biotech-to-announce-topline-results-of-pivotal-phase-3-trial-of-smndfr3pdv2n.html
[2] https://www.globenewswire.com/news-release/2025/08/10/3130545/0/en/IO-Biotech-to-Announce-Topline-Results-of-Pivotal-Phase-3-Trial-of-Cylembio-in-Combination-with-KEYTRUDA-pembrolizumab-as-a-First-Line-Treatment-for-Patients-with-Advanced-Melanoma.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet